MAPT and Alzheimer disease: Baseline studies of CSF from Alzheimer’s Disease Neuroimaging Initiative patients indicate that expected values for tau are 122 (± 58) pg/mL in AD patients and 70 (± 30) pg/mL in cognitively normal control patients; mean values for aβ42 are 144 (± 41) pg/mL in AD patients and 206 (± 55) pg/mL in control patients; and anticipated values for phosphorylated tau at the 181 site are 42 (± 20) pg/mL in AD patients and 25 (± 15) pg/mL in CSF from control patients [38].